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Performing certain invasive procedures, sometimes referred
to as ‘‘exposure-prone procedures’’ poses a risk of transmis-
sion of blood-borne infections, although the risk across pro-
cedures is not equal (Table 1). While there has been much
focus on patient-to-provider and patient-to-patient transmis-
sion of blood-borne infections, provider-to-patient transmis-
sion has also received attention. When a provider has known
hepatitis B (HBV) or hepatitis C (HCV) viral infections, what
is the provider’s moral responsibility to report his or her
infected status if they perform invasive procedures? To whom
should they report their infection? Do providers infected with
HBV or HCV have a duty to disclose their infected status
to their patients prior to any invasive procedures?
Risk of Viral Transmission From Provider
to Patient
In 1991, the Centers for Disease Control and Prevention
(CDC), acting in response to concerns over the possibility of
hepatitis B transmission from providers to patients, issued
guidelines for the management of HBV infection in health
care providers and students.1 Among these recommendations
were requirements that infected health care providers should
know their HBV disease status (namely their surface antigen
[HBsAg] and e antigen [HBeAg] status), that providers with
HBeAg-positive HBV notify and be guided by a clinical prac-
tice expert review panel at their local institution, and that
HBV-infected providers who performed exposure-prone pro-
cedures should be required to disclose their status to patients
prior to performing any procedure.1 There were no specific
recommendations made regarding HCV-positive providers,
because data was too limited at that time. The first docu-
mented US cases of provider-to-patient HBV and HCV infec-
tion were reported in the mid-1990s.2,3 Since that time, there
have been a total of approximately 500 documented cases
of provider-to-patient transmission of HBV worldwide and
approximately 400 documented cases of HCV.4 It is worth
noting that 275 of these cases were linked to a single Spanish
anesthesiology provider, where injection drug use, drug
diversion, and reinjection of patients after use of intravenous
needles by the provider was suspected.
In 2012, the CDC issued new guidance regarding the man-
agement of HBV-infected providers, though again, they offered
no guidance for HCV-infected providers.5 These and other
guidelines note that there is a clear professional and ethical
duty for providers who perform exposure-prone procedures to
know their HBV, HCV, and HIV status.3,5 For providers known
to be infected with these viruses and who perform exposure-
prone procedures, a multidisciplinary expert panel should pro-
vide oversight of the infected provider’s practice (Table 3).3,5
Additional guidelines published over the years have provided
similar guidance, but, in the most recent guidelines, the CDC
reversed its policy on routine mandatory disclosure, citing the
low risk of infection and possibility of harm to both providers
and patients.
Right to Privacy Versus Patient Safety
With respect to the ethical responsibility of a provider to
routinely disclose infected status to patients, there are several
competing ethical principles at stake: the provider’s right to
privacy and freedom from unjust discrimination due to their
medical condition and the patient’s right to be protected from
harm and to make an informed decision regarding medical
procedures. From the provider’s perspective, routine manda-
tory disclosure to patients represents a breach of confidential-
ity that can functionally result in a restriction of practice, loss
of privacy, and discrimination, even if risk of transmission is
extremely low. Multiple medical societies both in the United
States and internationally have not required mandatory
disclosure because the risk to the patient is so low, even with
exposure-prone procedures, that it does not outweigh the
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provider’s right to confidentiality (Table 2). This is particularly
true given Health System that mandatory disclosure would
likely result in limitation of practice, if not outright loss of all
health care practice.3,4
Patients, however, perceive that a right to know such
risks is important. Surveys have shown that a large majority
(>80%) of patients want to know when their health care
providers are infected with bloodborne viruses and that a
substantial percentage (34%) believe that infected pro-
viders should not practice at all.6 However, the patient’s
perceived risk of infection may not match the actual risk.
The institution of Standard Precautions, routine double-
TABLE 1 Categories of Procedures According to Level of Risk for Provider-to-Patient Bloodborne Pathogen Transmission
Category Examples of Procedures*,†
Minimal to no risk  Routine history and physical examination
 Routine dental exam, including gloved oral exam with mirror and/or tongue depressor or probe
 Routine rectal or vaginal exam with gloved hand
 Minor suturing
 Lower gastrointestinal tract procedures (ie, colonoscopy and sigmoidoscopy)
 Elective peripheral phlebotomy
Theoretical risk
but unlikely
 Upper gastrointestinal endoscopic procedures
 Bronchoscopy
 Minor local procedures (eg, abscess drainage, biopsy) under local anesthesia
when provider’s hands remain outside a body cavity
 Central vein and arterial line insertion, maintenance, and drug administration




 Most forms of major surgery, including general, orthopedic, neurosurgery, oral surgery, cardiothoracic
 Obstetrical and gynecologic surgery, including cesarean section, vaginal deliveries, forceps delivery,
episiotomy and any procedure involving hand-guided sharps
 Transplant surgery (except skin and corneal transplantation)
 Any procedure where there is digital palpation of needle tip in a body cavity or
where provider’s fingers and needle, sharp instrument, or object (eg, bone fragment)
are in poorly visualized or confined anatomic spaces
 Interactions with violent or seizing patients where the risk of patient biting a provider is high
Adapted from Henderson et al3 and Centers for Disease Control and Prevention Guidelines.5
*This list is not exhaustive. For the complete list, see Henderson et al3 and Centers for Disease Control and Prevention.5
†All procedures and physical examinations listed assume proper Standard Precautions are utilized, including use of gloves where appropriate.
TABLE 2 Comparison of Recommendations for Management of Health Care Providers With HBV and HCV Infection Who Perform Exposure-Prone Procedures
Requirements* CDC (2012)5 SHEA (2010)3 Europe (2003)10
HBV Monitoring
HBe Ag Not required to be negative Not required to be negative Required to be negative
HBV DNA <1000 IU/mL <2000 IU/mL <2000 IU/mL
Frequency  Providers with HBV DNA at or
below cutoff without treatment:
every 6 months
 Patients on treatment may require
more frequent monitoring
 Providers with HBV DNA at
or below cutoff without treatment:
every 6 months
 Patients on treatment may
require more frequent monitoring
 HbeAg-positive or treated providers with
HBV DNA below cutoff: every 3 months†
 Providers with HBV DNA at or below cutoff
without treatment: annual testing
Mandatory Disclosure Requirements
To patients No‡ No No
To expert panel Yes Yes Yes
HCV Monitoring
HCV RNA NA <2000 IU/mL§ -
Frequency NA every 6 months -
Disclosure requirements
To patients NA No No††
To expert panel NA Yes§ No††
*Requirements for performing exposure-prone procedures without restrictions.
†For providers on treatment, monitoring may be more frequent.
‡Exceptions include providers who have had prior transmission of viral infection to patients and instances where a blood exposure has or is suspected
to have occurred. In this latter instance, all guidelines recommend notifying the patient.
§All providers with positive HCV levels should report to their expert review panel and be guided by panel recommendations regarding ability to perform
of exposure-prone procedures, frequency of monitoring, and use of infection-control interventions.
††Recommendations not made based on lack of evidence.
Abbreviations: CDC, Centers for Disease Control and Prevention; SHEA, Society for Healthcare Epidemiology of America.
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gloving during invasive procedures, widespread hepatitis B
vaccination, attention to infection control guidelines, and
more effective treatments for both HBV and HCV have all
worked together to decrease the already low risk of
provider-to-patient transmission.7 In fact, there has been
only one reported instance of HBV infection from provider
to patient in the United States since 1996 and no cases of
HCV transmission in the United States from exposure-prone
procedures since 2001.4,5,8,9 The most recent HBV case
occurred in 2009 and involved an HBV-infected surgeon
who had been previously vaccinated but had, unbeknownst
to the surgeon, not achieved sufficient levels of HBsAb to
warrant protection from infection.8 There have been several
reports of provider-to-patient HCV transmission in the
United States since 2000, but these have been found to be
largely due to drug diversion in providers with opioid
addiction.9
Because of this extremely low risk of transmission, guide-
lines now advocate against routine mandatory disclosure of
infected status to patients, arguing that this is an unethical
and unnecessary breach of the provider’s right to privacy. In
addition, mandatory disclosure may be harmful to patients
as well as providers because it could lead to a reluctance to
be tested for viral infection and to be guided by an expert
panel for oversight of practice. Mandatory disclosure could
also lead to an unnecessary limitation in access to medical
care due to overzealous restrictions in practice.5 In other
areas of medical practice where providers are or have been
impaired (such as medical, psychiatric, or substance abuse
issues), mandatory disclosure is not required and practice is
not restricted, provided the health care worker is under
treatment for the condition and does not pose a risk to
patient safety. In a similar manner, infected providers with
viral loads above recommended levels (Table 2) can and
should be treated to reduce the viral load to lower levels,
before the provider performs exposure-prone procedures. In
addition, patients who are infected with HBV or HCV are
not required to disclose this to providers and, even in the
case of a patient-to-provider bloodborne infection exposure,
can decline to be tested for viral infections. To impose man-
datory patient disclosure requirements on HBV- or HCV-
infected providers would be a double standard that is diffi-
cult to justify in the face of existing evidence.
There are exceptions to nondisclosure to patients, however;
in cases where there has been documented transmission from
an infected provider to a patient or when a provider with a
viral load above recommended levels (Table 2) will be per-
forming an exposure-prone procedure, informed consent
should be provided prior to the procedure.3,5 When an
infected provider has exposed a patient to a bloodborne
infection, patients should be notified that the exposure has
occurred and offered appropriate follow-up, treatment, and
counseling, in a similar manner as when exposure from an
infected patient to a provider or from one infected patient to
another patient occurs. In these cases, the provider’s confi-
dentiality should be maintained as much as possible.
Conclusions
To protect patients, providers have a moral and professional
obligation to follow Standard Precautions (formerly known as
universal precautions), including double-gloving for exposure-
prone procedures, knowing their infection status with respect
to HBV, HCV, and HIV, and obtaining hepatitis B vaccination.
For those providers known to be infected who perform
exposure-prone procedures, their status should be disclosed to
an expert review panel to help determine if and when scope of
TABLE 3 Guidance for Responsibilities of Institutional Expert Review Panels
Only infected providers who perform exposure-prone procedures
(see Table 1) should have panel oversight. Providers who do
not perform exposure-prone procedures should be managed
as a personal health care issue
Expert review panels should evaluate infected providers’:
 Clinical and viral burden status
 Practices, procedures, techniques, and experience
 Adherence to recommended procedural technique
Expert review panels should also:
 Provide oversight of infected provider’s continued practice,
recommendations, and counseling as needed
 Investigate and notify appropriate persons and authorities
(such as medical licensing boards or risk management) in
the event of a patient exposure or suspected or documented
breach in procedure
 Reinforce Standard Precautions
 Provide noncoercive counseling regarding alternate
procedure or specialty paths
 Develop a written contract with the provider, detailing provider
and panel responsibilities*
Composition of the panel should be multidisciplinary and could include,
but is not limited to, members from the following:
 Persons with expertise in the provider’s specialty
 Liver disease specialist
 Infectious disease specialist
 Infected provider’s primary care physician
 Human resource personnel
 Occupational health
 Ethicists
 Hospital administrators/hospital director
 Hospital clinical affairs/risk management personnel
A protocol should be in place to communicate to patients when a
provider-to-patient exposure has or may have occurred.
Patients with possible or confirmed exposures should be offered
appropriate follow-up including postexposure vaccination and
treatment (ie, hepatitis B immune globulin and follow-up
testing for HBV exposure)
Confidentiality of the infected provider should always be respected,
as with any patient
Compiled from Henderson et al3 and Centers for Disease Control
and Prevention.5 In cases where a provider is not based in a single
institution, city, county, or state-level panels should be created. A min-
imum of two yearly meetings, either face-to-face or via conference call,
is suggested, but meetings could be called more frequently as need
requires.3
*A sample contract and description of contract elements can be
found in Henderson et al.3 Because state law differs in what aspects of the
contract are required, panels should consult with relevant legal experts.
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practice should be restricted based on their viral load status
(Table 3). For infected providers whose viral loads are above
recommended levels, antiviral therapy can be used to
reduce viral loads before a provider performs exposure-prone
procedures. Mandatory routine disclosure to patients, however,
should not be required because the risk of infection is too low to
warrant overriding provider confidentiality.n
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